Holen Sie sich die Stockscreener-App
0.8201
4.64%
-0.0399
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.86
Offen:
$0.899
24-Stunden-Volumen:
169.39K
Relative Volume:
0.59
Marktkapitalisierung:
$9.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.1374
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
-17.99%
1M Leistung:
-46.05%
6M Leistung:
-91.11%
1J Leistung:
-95.53%
1-Tages-Spanne:
$0.81
$0.90
1-Wochen-Bereich:
$0.8086
$1.0118
52-Wochen-Spanne:
$0.8086
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8201 | 9.36M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Pharmaceuticals stock hits 52-week low at $0.92 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals (CTXR) Price Target Adjusted to $4 Amid S - GuruFocus
Citius Pharmaceuticals stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.94 - Investing.com Australia
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Pharmaceuticals stock hits 52-week low at $1.21 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $1.21 By Investing.com - Investing.com India
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock - MSN
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com Australia
Citius Pharmaceuticals announces $2M registered direct offering of common stock - TipRanks
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) To Breakeven Soon - simplywall.st
Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $1.45 - Investing.com India
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st
Fisher Asset Management LLC Acquires Shares of 12,800 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates - TipRanks
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital - Defense World
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Pharmaceuticals stock hits 52-week low at $2.43 By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals stock hits 52-week low at $2.43 - Investing.com India
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology Inc. (CTOR) reports earnings - Quartz
Citius Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - Financial Times
Citius Pharmaceuticals (CTXR) Projected to Post Quarterly Earnings on Wednesday - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World
Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria
Dr Reddy's Signed Agreement With Citius Pharma To Sell Anti-Cancer Drug - BW Healthcare World
Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):